GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Euroapi SA (XPAR:EAPI) » Definitions » Additional Paid-In Capital

Euroapi (XPAR:EAPI) Additional Paid-In Capital : €1,861.3 Mil(As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Euroapi Additional Paid-In Capital?


Euroapi's quarterly additional paid-in capital declined from Dec. 2023 (€1,861.8 Mil) to Jun. 2024 (€1,861.3 Mil) but then stayed the same from Jun. 2024 (€1,861.3 Mil) to Dec. 2024 (€1,861.3 Mil).

Euroapi's annual additional paid-in capital declined from Dec. 2022 (€1,862.3 Mil) to Dec. 2023 (€1,861.8 Mil) and declined from Dec. 2023 (€1,861.8 Mil) to Dec. 2024 (€1,861.3 Mil).

Euroapi Additional Paid-In Capital Historical Data

The historical data trend for Euroapi's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Euroapi Additional Paid-In Capital Chart

Euroapi Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Additional Paid-In Capital
Get a 7-Day Free Trial - - 1,862.30 1,861.80 1,861.30

Euroapi Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,862.30 1,861.80 1,861.80 1,861.30 1,861.30

Euroapi Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Euroapi Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Euroapi's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Euroapi Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Euroapi SA (XPAR:EAPI) » Definitions » Additional Paid-In Capital
Comparable Companies
XPAR:BOI XPAR:AB XPAR:MLCOT XPAR:ALRPD XPAR:VETO ZTS XTER:MRK LSE:HLN NSE:SUNPHARMA TSE:4502 XSWX:GALD XSWX:SDZ NSE:DIVISLAB HKSE:03692 XTAE:TEVA SHSE:688506 BOM:500087 SZSE:000538 TSE:4507 UTHR
Traded in Other Exchanges
EAPIF:USA 0EAP:UK 940:Germany
Address
15 rue Traversiere, Paris, FRA, 75012
Website
https://www.euroapi.com
Euroapi SA develops, manufactures, markets, and distributes Active Pharmaceutical Ingredients (APIs) and Intermediates used in the formulation of medicines for human and veterinary use, both from originators, generics, and cosmetics. The company offers vitamin B12, prostaglandins, oligonucleotides, peptides, corticoids and hormones, anti-infectives, opiates (morphine, codeine, thebaine, etc.), analgesics, etc. It also offers Contract Development Manufacturing Organization (CDMO) services to its customers. Geographically, the company generates maximum revenue from Europe, followed by North America, Asia-Pacific, and the Rest of the world.

Euroapi Headlines

No Headlines